PET and SPECT imaging in psychiatric disorders (Q36811276)

16 August 2017

1 reference

title

PET and SPECT imaging in psychiatric disorders (English)

1 reference

16 August 2017

Robert B Zipursky

1

1 reference

16 August 2017

Jeffrey H Meyer

series ordinal

2

1 reference

16 August 2017

N Paul Verhoeff

series ordinal

3

1 reference

16 August 2017

language of work or name

English

0 references

publication date

1 March 2007

1 reference

Canadian Journal of Psychiatry

16 August 2017

published in

1 reference

16 August 2017

volume

52

1 reference

16 August 2017

issue

3

1 reference

16 August 2017

page(s)

146-157

1 reference

Neuroreceptor imaging in psychiatric disorders.

16 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1177%2F070674370705200303

Antipsychotic drugs which elicit little or no parkinsonism bind more loosely than dopamine to brain D2 receptors, yet occupy high levels of these receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674370705200303

Endogenous dopamine lowers the dopamine D2 receptor density as measured by [3H]raclopride: implications for positron emission tomography of the human brain

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674370705200303

Single photon emission computerized tomography imaging of amphetamine-induced dopamine release in drug-free schizophrenic subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674370705200303

Schizophrenia is associated with elevated amphetamine-induced synaptic dopamine concentrations: evidence from a novel positron emission tomography method

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674370705200303

Increased baseline occupancy of D2 receptors by dopamine in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674370705200303

Increased dopamine transmission in schizophrenia: relationship to illness phases

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674370705200303

PET study of competition between intravenous cocaine and [11C]raclopride at dopamine receptors in human subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674370705200303

Cannabis induced dopamine release: an in-vivo SPECT study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674370705200303

Dopamine release in response to a psychological stress in humans and its relationship to early life maternal care: a positron emission tomography study using [11C]raclopride.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674370705200303

Methylphenidate response, psychopathology and tardive dyskinesia as predictors of relapse in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674370705200303

Central D2-dopamine receptor occupancy in schizophrenic patients treated with antipsychotic drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674370705200303

Dopamine blockade and clinical response: evidence for two biological subgroups of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674370705200303

Positron emission tomographic analysis of central D1 and D2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine. Relation to extrapyramidal side effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674370705200303

Optimal haloperidol dosage in first-episode psychosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674370705200303

Relationship between dopamine D(2) occupancy, clinical response, and side effects: a double-blind PET study of first-episode schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674370705200303

Mechanisms of action of second generation antipsychotic drugs in schizophrenia: insights from brain imaging studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674370705200303

Dopamine D(2) receptors and their role in atypical antipsychotic action: still necessary and may even be sufficient

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674370705200303

A PET study of dopamine D2 and serotonin 5-HT2 receptor occupancy in patients with schizophrenia treated with therapeutic doses of ziprasidone

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674370705200303

A PET study evaluating dopamine D2 receptor occupancy for long-acting injectable risperidone

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674370705200303

Atypical antipsychotics in the treatment of schizophrenia: systematic overview and meta-regression analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674370705200303

Treatment response to olanzapine and haloperidol and its association with dopamine D receptor occupancy in first-episode psychosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674370705200303

Comparative efficacy and safety of atypical and conventional antipsychotic drugs in first-episode psychosis: a randomized, double-blind trial of olanzapine versus haloperidol

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674370705200303

A positron emission tomography study of quetiapine in schizophrenia: a preliminary finding of an antipsychotic effect with only transiently high dopamine D2 receptor occupancy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674370705200303

Does fast dissociation from the dopamine d(2) receptor explain the action of atypical antipsychotics?: A new hypothesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674370705200303

Delayed normalization of central D2 dopamine receptor availability after discontinuation of haloperidol decanoate. Preliminary findings

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674370705200303

Clinical outcome following neuroleptic discontinuation in patients with remitted recent-onset schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674370705200303

Mechanism of action of antipsychotic drugs: from dopamine D(2) receptor antagonism to glutamate NMDA facilitation

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674370705200303

Subjective experience and striatal dopamine D(2) receptor occupancy in patients with schizophrenia stabilized by olanzapine or risperidone

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674370705200303

Occupancy of dopamine D2 receptors by antipsychotic drugs is related to nicotine addiction in young patients with schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674370705200303

Is regionally selective D2/D3 dopamine occupancy sufficient for atypical antipsychotic effect? an in vivo quantitative [123I]epidepride SPET study of amisulpride-treated patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674370705200303

Optimizing limbic selective D2/D3 receptor occupancy by risperidone: a [123I]-epidepride SPET study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674370705200303

Preparation of 11C-labelled Raclopride, a new potent dopamine receptor antagonist: preliminary PET studies of cerebral dopamine receptors in the monkey

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674370705200303

[18F]setoperone: a new high-affinity ligand for positron emission tomography study of the serotonin-2 receptors in baboon brain in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674370705200303

Novel radiotracers for imaging the serotonin transporter by positron emission tomography: synthesis, radiosynthesis, and in vitro and ex vivo evaluation of (11)C-labeled 2-(phenylthio)araalkylamines

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674370705200303

Elevated monoamine oxidase a levels in the brain: an explanation for the monoamine imbalance of major depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674370705200303

Occupancy of serotonin transporters by paroxetine and citalopram during treatment of depression: a [(11)C]DASB PET imaging study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674370705200303

Serotonin transporter occupancy of five selective serotonin reuptake inhibitors at different doses: an [11C]DASB positron emission tomography study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674370705200303

Elevated putamen D(2) receptor binding potential in major depression with motor retardation: an [11C]raclopride positron emission tomography study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674370705200303

Biogenic Amines and Emotion

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674370705200303

Dysfunctional attitudes and 5-HT2 receptors during depression and self-harm.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674370705200303

Increased 5-HT(2A) receptor binding in euthymic, medication-free patients recovered from depression: a positron emission study with [(11)C]MDL 100,907.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674370705200303

Imaging synaptic neurotransmission with in vivo binding competition techniques: a critical review

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674370705200303

Psychomotor Activity and Cerebrospinal Fluid Amine Metabolites in Affective Illness

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674370705200303

Uneven pattern of dopamine loss in the striatum of patients with idiopathic Parkinson's disease. Pathophysiologic and clinical implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674370705200303

Lower dopamine transporter binding potential in striatum during depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674370705200303

Brain serotonin transporter binding potential measured with carbon 11-labeled DASB positron emission tomography: effects of major depressive episodes and severity of dysfunctional attitudes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674370705200303

Fluvoxamine preferentially increases extracellular 5-hydroxytryptamine in the raphe nuclei: an in vivo microdialysis study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674370705200303

Primary structure of the human platelet serotonin uptake site: identity with the brain serotonin transporter.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674370705200303

Serotonin transporters are located on the axons beyond the synaptic junctions: anatomical and functional evidence

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674370705200303

Regional distribution of serotonin transporter protein in postmortem human brain: is the cerebellum a SERT-free brain region?

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674370705200303

Regional and subcellular localization in human brain of [3H]paroxetine binding, a marker of serotonin uptake sites

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674370705200303

High levels of serotonin transporter occupancy with low-dose clomipramine in comparative occupancy study with fluvoxamine using positron emission tomography

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674370705200303

Bupropion occupancy of the dopamine transporter is low during clinical treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674370705200303

In vivo activity of bupropion at the human dopamine transporter as measured by positron emission tomography

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674370705200303

Changes in human in vivo serotonin and dopamine transporter availabilities during chronic antidepressant administration

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674370705200303

Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674370705200303

Islington study of dementia subtypes in the community

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674370705200303

Vascular dementia: diagnostic criteria for research studies. Report of the NINDS-AIREN International Workshop

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674370705200303

Long-term efficacy and safety of donepezil in the treatment of Alzheimer's disease: an interim analysis of the results of a US multicentre open label extension study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674370705200303

Two-year treatment of Alzheimer's disease with eptastigmine. The Eptastigmine Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674370705200303

Galantamine, a cholinesterase inhibitor that allosterically modulates nicotinic receptors: effects on the course of Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674370705200303

Dementia: causes, evaluation, and management

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674370705200303

Donepezil is associated with delayed nursing home placement in patients with Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674370705200303

Galantamine in AD: A 6-month randomized, placebo-controlled trial with a 6-month extension. The Galantamine USA-1 Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674370705200303

Open-label, multicenter, phase 3 extension study of the safety and efficacy of donepezil in patients with Alzheimer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674370705200303

Practice parameter: diagnosis of dementia (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674370705200303

SPECT perfusion imaging in the diagnosis of Alzheimer's disease: a clinical-pathologic study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674370705200303

HMPAO SPET and FDG PET in Alzheimer's disease and vascular dementia: comparison of perfusion and metabolic pattern.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674370705200303

PET technology: current trends and future developments.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674370705200303

Neuropathological stageing of Alzheimer-related changes

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674370705200303

The biochemical pathway of neurofibrillary degeneration in aging and Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674370705200303

Tau pathology in Alzheimer disease and other tauopathies

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674370705200303

The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674370705200303

Phases of A beta-deposition in the human brain and its relevance for the development of AD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674370705200303

Physical basis of cognitive alterations in alzheimer's disease: Synapse loss is the major correlate of cognitive impairment

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674370705200303

Altered expression of synaptic proteins occurs early during progression of Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674370705200303

The Topographical and Neuroanatomical Distribution of Neurofibrillary Tangles and Neuritic Plaques in the Cerebral Cortex of Patients with Alzheimer's Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674370705200303

In vivo brain imaging of tangle burden in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674370705200303

Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674370705200303

Two-year follow-up of amyloid deposition in patients with Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674370705200303

Cerebral amyloid deposition and diffuse plaques in "normal" aging: Evidence for presymptomatic and very mild Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674370705200303

Mild cognitive impairment as a diagnostic entity

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674370705200303

Kinetic modeling of amyloid binding in humans using PET imaging and Pittsburgh Compound-B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674370705200303

Reduced cortical distribution volume of iodine-123 iomazenil in Alzheimer's disease as a measure of loss of synapses

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674370705200303

Frontotemporal lobar degeneration: a consensus on clinical diagnostic criteria

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674370705200303

10.1177/070674370705200303

21 January 2018

Identifiers

DOI

0 references

1 reference